Who founded Tonix Pharmaceuticals Holding?

Tonix Pharmaceuticals Holding was founded by Seth Lederman in 2008.

How much funding has Tonix Pharmaceuticals Holding raised?

Tonix Pharmaceuticals Holding has disclosed $4.6M raised across 2 of its 4 known rounds.

Where is Tonix Pharmaceuticals Holding headquartered?

Tonix Pharmaceuticals Holding is headquartered in New York, US.

Tonix Pharmaceuticals Holding

NASDAQ: TNXP

New York, US · Founded 2008 · Nevada corporation · 181 employees on LinkedIn

Find your way into Tonix Pharmaceuticals Holding

234 people in our graph share verified history with the Tonix Pharmaceuticals Holding team — schools, employers, funds. One of them is your warm intro.

Kevin Reeveyunlockedknows Rhonda Rosen · together at Putnam Lovell NBF (overlapped)

knows the team · via Early Growth

knows the team · via MediQuire

×3knows the team · via Putnam Lovell NBF

knows the team · via Burkland

knows the team · via SeatonHill Partners

Tonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.

Biotech Healthtech

Founders & leadership

Tonix Pharmaceuticals Holding was founded in 2008 by Seth Lederman.

Seth Lederman Founder · CEOA physician-scientist by training, he spent more than three decades at Columbia University, where he served as an associate professor from 1985 to 2017. He took on the chief executive role at Tonix Pharmaceuticals in 2014.

Gregory SullivanChief Medical Officer2014–2026

Bradley Saenger Chief Financial OfficerBradley Saenger is Chief Financial Officer and Treasurer at Tonix Pharmaceuticals, a biotechnology company developing therapies for central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. He has extensive experience in financial management, accounting systems, regulatory compliance including Sarbanes-Oxley and SEC reporting, and mergers and acquisitions.

Rhonda Rosen ExecutiveRhonda Rosen is Executive Officer at Tonix Pharmaceuticals Holding, a biotechnology company developing therapies for central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. She has expertise in financial operations, SEC reporting, and corporate transactions including mergers and acquisitions across financial services, biotech, and pharmaceutical sectors.

Benjamin SelzerExecutive

Ernest MarioNamed on SEC filing

Stuart DavidsonNamed on SEC filing

Donald W. LandryNamed on SEC filing

John RhodesNamed on SEC filing

Charles E. Mather IVNamed on SEC filing

Margaret Smith BellNamed on SEC filing

Board

Samuel SaksBoard director

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 2 of 4 rounds · 1900–2017

▶$314.8KraisedOct 2017 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Ernest MarioDirector
Gregory SullivanExecutive Officer
Bradley SaengerExecutive Officer
Stuart DavidsonDirector
Donald W. LandryDirector
Seth LedermanExecutive Officer, Director
John RhodesDirector
Charles E. Mather IVDirector
Samuel SaksDirector
Margaret Smith BellDirector
Patrick GraceDirector

Offering amount: $15.3M
Amount sold: $314.8K
First sale: Sep 2017
Incorporated: Corporation, Nevada
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.3MraisedJan 2012 · 81 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Patrick GraceDirector
Charles MatherDirector
Rhonda RosenExecutive Officer
John RhodesDirector
Stuart DavidsonDirector
Benjamin SelzerExecutive Officer
Ernest MarioDirector
Donald LandryDirector
Seth LedermanExecutive Officer, Director

Offering amount: $10M
Amount sold: $4.3M
Minimum investment: $10K
Sales commissions: $188.2K
Placement agents: DAWSON JAMES SECURITIES, INC
First sale: Jan 2012
Incorporated: Corporation, Nevada, 2008
Federal exemptions: 06

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$12.4Mvaluation at IPOFeb 2020 · $0.57/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 2

by search overlap

Robinhood112 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Seeking Alpha104 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies competing with Tonix Pharmaceuticals Holding for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Tonix Pharmaceuticals Holding do?: Tonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.
Who founded Tonix Pharmaceuticals Holding?: Tonix Pharmaceuticals Holding was founded by Seth Lederman in 2008.
How much funding has Tonix Pharmaceuticals Holding raised?: Tonix Pharmaceuticals Holding has disclosed $4.6M raised across 2 of its 4 known rounds.
Where is Tonix Pharmaceuticals Holding headquartered?: Tonix Pharmaceuticals Holding is headquartered in New York, US.